{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:12:19Z","timestamp":1793423539927,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72174207"],"award-info":[{"award-number":["72174207"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40259-023-00586-6","type":"journal-article","created":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T10:02:26Z","timestamp":1677319346000},"page":"421-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing"],"prefix":"10.1007","volume":"37","author":[{"given":"Taihang","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingye","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3564-3626","authenticated-orcid":false,"given":"Wenxi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,25]]},"reference":[{"issue":"3","key":"586_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"34","key":"586_CR2","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","volume":"33","author":"CM Rudin","year":"2015","unstructured":"Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American Society of clinical oncology endorsement of the American College of chest physicians guideline. J Clin Oncol. 2015;33(34):4106\u201311. https:\/\/doi.org\/10.1200\/JCO.2015.63.7918.","journal-title":"J Clin Oncol"},{"issue":"5","key":"586_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/cncr.29098","volume":"121","author":"LA Byers","year":"2015","unstructured":"Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121(5):664\u201372. https:\/\/doi.org\/10.1002\/cncr.29098.","journal-title":"Cancer"},{"issue":"1","key":"586_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.21037\/tlcr.2018.01.16","volume":"7","author":"AF Farago","year":"2018","unstructured":"Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018;7(1):69\u201379. https:\/\/doi.org\/10.21037\/tlcr.2018.01.16.","journal-title":"Transl Lung Cancer Res."},{"issue":"28","key":"586_CR5","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1200\/JCO.2009.23.1548","volume":"27","author":"MA Socinski","year":"2009","unstructured":"Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009;27(28):4787\u201392. https:\/\/doi.org\/10.1200\/JCO.2009.23.1548.","journal-title":"J Clin Oncol"},{"issue":"6","key":"586_CR6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(22)00224-8.","journal-title":"Lancet Oncol"},{"issue":"23","key":"586_CR7","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"issue":"6","key":"586_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39(6):619\u201330. https:\/\/doi.org\/10.1200\/JCO.20.01055.","journal-title":"J Clin Oncol"},{"issue":"1","key":"586_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30539-8.","journal-title":"Lancet Oncol"},{"issue":"2","key":"586_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408","volume":"7","author":"L Paz-Ares","year":"2022","unstructured":"Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2): 100408. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100408.","journal-title":"ESMO Open."},{"issue":"21","key":"586_CR11","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369\u201379. https:\/\/doi.org\/10.1200\/JCO.20.00793.","journal-title":"J Clin Oncol"},{"issue":"10","key":"586_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s40265-022-01740-0","volume":"82","author":"A Lee","year":"2022","unstructured":"Lee A. Serplulimab: first approval. Drugs. 2022;82(10):1137\u201341. https:\/\/doi.org\/10.1007\/s40265-022-01740-0.","journal-title":"Drugs"},{"issue":"15","key":"586_CR13","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1200\/JCO.2021.39.15_suppl.2566","volume":"39","author":"S Qin","year":"2021","unstructured":"Qin S, Li J, Zhong H, et al. Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: a single-arm, multicenter, phase 2 study. J Clin Oncol. 2021;39(15):2566\u20132566. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2566.","journal-title":"J Clin Oncol"},{"issue":"16","key":"586_CR14","doi-asserted-by":"publisher","first-page":"8505","DOI":"10.1200\/JCO.2022.40.16_suppl.8505","volume":"40","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, et al. Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: an international randomized phase 3 study. J Clin Oncol. 2022;40(16):8505\u20138505. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.8505.","journal-title":"J Clin Oncol"},{"issue":"12","key":"586_CR15","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328(12):1223\u201332. https:\/\/doi.org\/10.1001\/jama.2022.16464.","journal-title":"JAMA"},{"key":"586_CR16","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines for Small Cell Lung Cancer. https:\/\/www.nccn.org\/profile?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf. Accessed 28 August, 2022"},{"key":"586_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.01.019","volume":"130","author":"K Zhou","year":"2019","unstructured":"Zhou K, Zhou J, Huang J, et al. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung Cancer. 2019;130:1\u20134. https:\/\/doi.org\/10.1016\/j.lungcan.2019.01.019.","journal-title":"Lung Cancer"},{"key":"586_CR18","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7796","author":"D Ding","year":"2021","unstructured":"Ding D, Hu H, Li S, et al. Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer. J Natl Compr Canc Netw. 2021. https:\/\/doi.org\/10.6004\/jnccn.2020.7796.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"586_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0300891620985309","volume":"108","author":"YH Tong","year":"2022","unstructured":"Tong YH, Ding HY, Xin WX, et al. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers\u2019 perspective. Tumori. 2022;108(1):33\u20139. https:\/\/doi.org\/10.1177\/0300891620985309.","journal-title":"Tumori"},{"issue":"1","key":"586_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/14737167.2021.1888717","volume":"22","author":"G Liu","year":"2022","unstructured":"Liu G, Kang S. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. Expert Rev Pharmacoecon Outcomes Res. 2022;22(1):85\u201391. https:\/\/doi.org\/10.1080\/14737167.2021.1888717.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"23","key":"586_CR21","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1097\/CM9.0000000000000536","volume":"132","author":"L Li","year":"2019","unstructured":"Li L, Wang H, Chen X, Li W, Cui J. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China. Chin Med J (Engl). 2019;132(23):2790\u20134. https:\/\/doi.org\/10.1097\/CM9.0000000000000536.","journal-title":"Chin Med J (Engl)"},{"key":"586_CR22","unstructured":"Redsenol. The price and the PAP of Serplulimab. https:\/\/redsenol.com\/28821.html. Accessed 29 August, 2022"},{"issue":"1","key":"586_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351.","journal-title":"Value Health."},{"issue":"6","key":"586_CR24","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jval.2011.04.004","volume":"14","author":"B Goulart","year":"2011","unstructured":"Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health. 2011;14(6):836\u201345. https:\/\/doi.org\/10.1016\/j.jval.2011.04.004.","journal-title":"Value Health."},{"issue":"10","key":"586_CR25","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.clinthera.2011.09.016","volume":"33","author":"B Wu","year":"2011","unstructured":"Wu B, Chen H, Shen J, Ye M. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China. Clin Ther. 2011;33(10):1446\u201355. https:\/\/doi.org\/10.1016\/j.clinthera.2011.09.016.","journal-title":"Clin Ther"},{"issue":"4","key":"586_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/0272989X16670617","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey JD, Mackay DF, Briggs AH. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and markov decision-analytic modeling. Med Decis Making. 2017;37(4):427\u201339. https:\/\/doi.org\/10.1177\/0272989X16670617.","journal-title":"Med Decis Making"},{"issue":"8","key":"586_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40273-013-0064-3","volume":"31","author":"KJ Ishak","year":"2013","unstructured":"Ishak KJ, Kreif N, Benedict A, Muszbek N. Overview of parametric survival analysis for health-economic applications. Pharmacoeconomics. 2013;31(8):663\u201375. https:\/\/doi.org\/10.1007\/s40273-013-0064-3.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"586_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0037","volume":"4","author":"D Su","year":"2021","unstructured":"Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021;4(2): e210037. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0037.","journal-title":"JAMA Netw Open."},{"issue":"9","key":"586_CR29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jama.2020.0734","volume":"323","author":"JL Dieleman","year":"2020","unstructured":"Dieleman JL, Cao J, Chapin A, et al. US health care spending by payer and health condition, 1996\u20132016. JAMA. 2020;323(9):863\u201384. https:\/\/doi.org\/10.1001\/jama.2020.0734.","journal-title":"JAMA"},{"key":"586_CR30","unstructured":"Guoen L. Chinese guidelines for pharmacoeconomics evaluation 2020. China Market Press; 2020"},{"key":"586_CR31","unstructured":"National Bureau of Statistics. 2021 Statistical Bulletin of National Economic and Social Development. http:\/\/www.stats.gov.cn\/xxgk\/jd\/sjjd2020\/202202\/t20220228_1827972.html. Accessed 25 March, 2022"},{"key":"586_CR32","unstructured":"National Institute for Clinical Excellence. Developing NICE guidelines: the manual. www.nice.org.uk\/process\/pmg20. Accessed 29 August, 2022"},{"issue":"9","key":"586_CR33","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137. https:\/\/doi.org\/10.1056\/NEJMp1405158.","journal-title":"N Engl J Med"},{"key":"586_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"586_CR35","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1177\/0272989X19873661","volume":"39","author":"B Kearns","year":"2019","unstructured":"Kearns B, Stevenson MD, Triantafyllopoulos K, Manca A. Generalized linear models for flexible parametric modeling of the hazard function. Med Decis Making. 2019;39(7):867\u201378. https:\/\/doi.org\/10.1177\/0272989X19873661.","journal-title":"Med Decis Making"},{"key":"586_CR36","unstructured":"The National Institute for Health and Care Excellence. NICE DSU technical support document 21: Flexible Methods for Survival Analysis. https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/TSD21-Flex-Surv-TSD-21_Final_alt_text.pdf. Accessed 3 April, 2022"},{"issue":"1","key":"586_CR37","doi-asserted-by":"publisher","first-page":"238146832210896","DOI":"10.1177\/23814683221089659","volume":"7","author":"PV Federico","year":"2022","unstructured":"Federico PV, Kurt M, Zhang L, et al. Heterogeneity in survival with immune checkpoint inhibitors and its implications for survival extrapolations: a case study in advanced melanoma. MDM Policy Pract. 2022;7(1):23814683221089660. https:\/\/doi.org\/10.1177\/23814683221089659.","journal-title":"MDM Policy Pract."},{"key":"586_CR38","unstructured":"MENET. MENET.com.cn. https:\/\/www.menet.com.cn\/. Accessed 25 March, 2022"},{"key":"586_CR39","unstructured":"Yaoch. YAOZH.com. https:\/\/www.yaozh.com\/. Accessed 25 March, 2022"},{"key":"586_CR40","unstructured":"Centers for Medicare & Medicaid Services. 2022 ASP Drug Pricing Files. https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2022-asp-drug-pricing-files. Accessed 28 August, 2022"},{"key":"586_CR41","unstructured":"Centers for Medicare & Medicaid Services. 2022 Physician Fee Schedule. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search. Accessed 28 August, 2022"},{"issue":"15","key":"586_CR42","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1200\/jco.2012.30.15_suppl.2548","volume":"30","author":"L Amiri-Kordestani","year":"2012","unstructured":"Amiri-Kordestani L, Wilkerson J, Balasubramaniam S, Bates SE, Fojo AT. Difference between duration of treatment (DOT) and progression-free survival (PFS) as a marker of unbalanced censoring. J Clin Oncol. 2012;30(15):2548\u20132548. https:\/\/doi.org\/10.1200\/jco.2012.30.15_suppl.2548.","journal-title":"J Clin Oncol"},{"key":"586_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.912921","author":"T Shao","year":"2022","unstructured":"Shao T, Ren Y, Zhao M, Tang W. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China. Front Public Health. 2022. https:\/\/doi.org\/10.3389\/fpubh.2022.912921.","journal-title":"Front Public Health"},{"issue":"1","key":"586_CR44","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/13696998.2022.2071066","volume":"25","author":"M Rui","year":"2022","unstructured":"Rui M, Fei Z, Wang Y, et al. Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China. J Med Econ. 2022;25(1):618\u201329. https:\/\/doi.org\/10.1080\/13696998.2022.2071066.","journal-title":"J Med Econ"},{"issue":"3","key":"586_CR45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s41669-018-0115-y","volume":"3","author":"A Bullement","year":"2019","unstructured":"Bullement A, Nathan P, Willis A, et al. Cost effectiveness of avelumab for metastatic merkel cell carcinoma. Pharmacoecon Open. 2019;3(3):377\u201390. https:\/\/doi.org\/10.1007\/s41669-018-0115-y.","journal-title":"Pharmacoecon Open."},{"issue":"2","key":"586_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jval.2021.08.009","volume":"25","author":"A Kuznik","year":"2022","unstructured":"Kuznik A, Smare C, Chen CI, et al. Cost-effectiveness of cemiplimab versus standard of care in the united states for first-line treatment of advanced non-small cell lung cancer with programmed death-ligand 1 expression >\/=50. Value Health. 2022;25(2):203\u201314. https:\/\/doi.org\/10.1016\/j.jval.2021.08.009.","journal-title":"Value Health."},{"key":"586_CR47","unstructured":"National Institute for Health and Clinical Excellence. Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer. https:\/\/www.nice.org.uk\/guidance\/ta638\/evidence. Accessed 28 August, 2022"},{"issue":"2","key":"586_CR48","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11136-020-02615-1","volume":"30","author":"A Vedadi","year":"2021","unstructured":"Vedadi A, Shakik S, Brown MC, et al. The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data. Qual Life Res. 2021;30(2):445\u201354. https:\/\/doi.org\/10.1007\/s11136-020-02615-1.","journal-title":"Qual Life Res"},{"issue":"5","key":"586_CR49","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1111\/ajco.12477","volume":"13","author":"B Nafees","year":"2017","unstructured":"Nafees B, Lloyd AJ, Dewilde S, Rajan N, Lorenzo M. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13(5):e195\u2013203. https:\/\/doi.org\/10.1111\/ajco.12477.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"586_CR50","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/0886022X.2020.1735417","volume":"42","author":"Y Li","year":"2020","unstructured":"Li Y, Chen X, Shen Z, et al. Electrolyte and acid-base disorders in cancer patients and its impact on clinical outcomes: evidence from a real-world study in China. Ren Fail. 2020;42(1):234\u201343. https:\/\/doi.org\/10.1080\/0886022X.2020.1735417.","journal-title":"Ren Fail"},{"issue":"5","key":"586_CR51","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10198-012-0419-2","volume":"14","author":"K Tolley","year":"2013","unstructured":"Tolley K, Goad C, Yi Y, et al. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ. 2013;14(5):749\u201359. https:\/\/doi.org\/10.1007\/s10198-012-0419-2.","journal-title":"Eur J Health Econ"},{"issue":"3","key":"586_CR52","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40258-020-00620-6","volume":"19","author":"AJ Hatswell","year":"2021","unstructured":"Hatswell AJ, Bullement A, Schlichting M, Bharmal M. What is the impact of the analysis method used for health state utility values on QALYs in oncology? A simulation study comparing progression-based and time-to-death approaches. Appl Health Econ Health Policy. 2021;19(3):389\u2013401. https:\/\/doi.org\/10.1007\/s40258-020-00620-6.","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"586_CR53","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s41669-017-0045-0","volume":"2","author":"A Enstone","year":"2018","unstructured":"Enstone A, Greaney M, Povsic M, et al. The economic burden of small cell lung cancer: a systematic review of the literature. Pharmacoecon Open. 2018;2(2):125\u201339. https:\/\/doi.org\/10.1007\/s41669-017-0045-0.","journal-title":"Pharmacoecon Open."},{"issue":"6","key":"586_CR54","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1001\/jamaoncol.2019.0081","volume":"5","author":"V Mor","year":"2019","unstructured":"Mor V, Wagner TH, Levy C, et al. Association of expanded VA hospice care with aggressive care and cost for veterans with advanced lung cancer. JAMA Oncol. 2019;5(6):810\u20136. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0081.","journal-title":"JAMA Oncol"},{"key":"586_CR55","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1186\/1471-2407-14-984","volume":"14","author":"B Wu","year":"2014","unstructured":"Wu B, Li T, Cai J, Xu Y, Zhao G. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer. 2014;14:984. https:\/\/doi.org\/10.1186\/1471-2407-14-984.","journal-title":"BMC Cancer"},{"key":"586_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12962-021-00329-w","volume":"19","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Hu H, Ding D, et al. First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis. Cost Eff Resour Alloc. 2021;19:1. https:\/\/doi.org\/10.1186\/s12962-021-00329-w.","journal-title":"Cost Eff Resour Alloc."},{"key":"586_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.602185","author":"L Zhang","year":"2020","unstructured":"Zhang L, Hang Y, Liu M, Li N, Cai H. First-line durvalumab plus platinum-etoposide versus platinum-etoposide for extensive-stage small-cell lung cancer: a cost-effectiveness analysis. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.602185.","journal-title":"Front Oncol"},{"key":"586_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.699781","author":"Q Liu","year":"2021","unstructured":"Liu Q, Luo X, Yi L, Zeng X, Tan C. First-line chemo-immunotherapy for extensive-stage small-cell lung cancer: a united states-based cost-effectiveness analysis. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.699781.","journal-title":"Front Oncol"},{"key":"586_CR59","doi-asserted-by":"publisher","first-page":"740091","DOI":"10.3389\/fonc.2021.740091","volume":"11","author":"S Kang","year":"2021","unstructured":"Kang S, Wang X, Zhang Y, et al. First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a network meta-analysis and cost-effectiveness analysis. Front Oncol. 2021;11:740091\u2013740091. https:\/\/doi.org\/10.3389\/fonc.2021.740091.","journal-title":"Front Oncol"},{"key":"586_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.650392","author":"Y Wang","year":"2021","unstructured":"Wang Y, Rui M, Yang L, et al. Economic evaluation of first-line atezolizumab for extensive-stage small-cell lung cancer in the US. Front Public Health. 2021. https:\/\/doi.org\/10.3389\/fpubh.2021.650392.","journal-title":"Front Public Health"},{"issue":"11","key":"586_CR61","doi-asserted-by":"publisher","first-page":"e2013","DOI":"10.1002\/onco.13954","volume":"26","author":"S Lin","year":"2021","unstructured":"Lin S, Luo S, Gu D, et al. First-line durvalumab in addition to etoposide and platinum for extensive-stage small cell lung cancer: a US-basedcost-effectiveness analysis. Oncologist. 2021;26(11):e2013\u201320. https:\/\/doi.org\/10.1002\/onco.13954.","journal-title":"Oncologist"},{"issue":"11","key":"586_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258605","volume":"16","author":"Q Liu","year":"2021","unstructured":"Liu Q, Tan C, Yi L, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer. PLoS ONE. 2021;16(11): e0258605. https:\/\/doi.org\/10.1371\/journal.pone.0258605.","journal-title":"PLoS ONE"},{"issue":"6","key":"586_CR63","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40261-022-01157-3","volume":"42","author":"Y Ionova","year":"2022","unstructured":"Ionova Y, Vuong W, Sandoval O, et al. Cost-effectiveness analysis of atezolizumab versus durvalumab as first-line treatment of extensive-stage small-cell lung cancer in the USA. Clin Drug Investig. 2022;42(6):491\u2013500. https:\/\/doi.org\/10.1007\/s40261-022-01157-3.","journal-title":"Clin Drug Investig"},{"key":"586_CR64","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1186\/s12913-014-0555-8","volume":"14","author":"SJ Karve","year":"2014","unstructured":"Karve SJ, Price GL, Davis KL, et al. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers. BMC Health Serv Res. 2014;14:555. https:\/\/doi.org\/10.1186\/s12913-014-0555-8.","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"586_CR65","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jama.2022.16442","volume":"328","author":"NJ Choudhury","year":"2022","unstructured":"Choudhury NJ, Riely GJ. Serplulimab with chemotherapy in extensive-stage SCLC. JAMA. 2022;328(12):1205\u20137. https:\/\/doi.org\/10.1001\/jama.2022.16442.","journal-title":"JAMA"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00586-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00586-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00586-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:35:49Z","timestamp":1684431349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00586-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,25]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00586-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,25]]},"assertion":[{"value":"9 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Taihang Shao, Mingye Zhao, Leyi Liang, and Wenxi Tang declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"TS is the corresponding author. TS had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: All the authors. Acquisition, analysis, or interpretation of data: TS, MZ, LL. Drafting of the manuscript: TS. Critical revision of the manuscript for important intellectual content: MZ, LL, WT. Statistical analysis: TS, MZ. Obtained funding: WT. Administrative, technical, or material support: WT. Supervision: WT.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This work was sponsored by the General Program of National Natural Science Foundation of China (No. 72174207).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the funder\/sponsor"}},{"value":"All data generated or analyzed during this study are included in this article and its supplementary materials.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"The models and codes for reproducing this study can be found on GitHub (\n                      \n                      ).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent for participation and publication"}}]}}